405 related articles for article (PubMed ID: 19452131)
1. Skin toxicities associated with epidermal growth factor receptor inhibitors.
Li T; Perez-Soler R
Target Oncol; 2009 Apr; 4(2):107-19. PubMed ID: 19452131
[TBL] [Abstract][Full Text] [Related]
2. The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab.
Perez-Soler R; Zou Y; Li T; Ling YH
Clin Cancer Res; 2011 Nov; 17(21):6766-77. PubMed ID: 21914790
[TBL] [Abstract][Full Text] [Related]
3. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).
Jatoi A; Rowland K; Sloan JA; Gross HM; Fishkin PA; Kahanic SP; Novotny PJ; Schaefer PL; Johnson DB; Tschetter LK; Loprinzi CL
Cancer; 2008 Aug; 113(4):847-53. PubMed ID: 18543329
[TBL] [Abstract][Full Text] [Related]
4. Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE).
Chayahara N; Mukohara T; Tachihara M; Fujishima Y; Fukunaga A; Washio K; Yamamoto M; Nakata K; Kobayashi K; Takenaka K; Toyoda M; Kiyota N; Tobimatsu K; Doi H; Mizuta N; Marugami N; Kawaguchi A; Nishigori C; Nishimura Y; Minami H
Oncologist; 2019 Jul; 24(7):885-e413. PubMed ID: 30890624
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Ready N
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
[TBL] [Abstract][Full Text] [Related]
6. Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.
Chou LS; Garey J; Oishi K; Kim E
Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S15-22. PubMed ID: 17239286
[TBL] [Abstract][Full Text] [Related]
7. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4).
Jatoi A; Thrower A; Sloan JA; Flynn PJ; Wentworth-Hartung NL; Dakhil SR; Mattar BI; Nikcevich DA; Novotny P; Sekulic A; Loprinzi CL
Oncologist; 2010; 15(9):1016-22. PubMed ID: 20798191
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity.
Parmar S; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seeringer A; Paul T; Seufferlein T; Stingl JC
Pharmacogenomics J; 2013 Apr; 13(2):181-8. PubMed ID: 22158333
[TBL] [Abstract][Full Text] [Related]
9. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
Perez-Soler R
Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S7-14. PubMed ID: 17239291
[TBL] [Abstract][Full Text] [Related]
10. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
11. Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study.
Grande R; Narducci F; Bianchetti S; Mansueto G; Gemma D; Sperduti I; Trombetta G; Angelini F; Gamucci T
Support Care Cancer; 2013 Jun; 21(6):1691-5. PubMed ID: 23314653
[TBL] [Abstract][Full Text] [Related]
12. Advances in EGFR-directed therapy in head and neck cancer.
Numico G; Silvestris N; Grazioso Russi E
Front Biosci (Schol Ed); 2011 Jan; 3(2):454-66. PubMed ID: 21196389
[TBL] [Abstract][Full Text] [Related]
13. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
Nardone B; Nicholson K; Newman M; Guitart J; Gerami P; Talarico N; Yang XJ; Rademaker A; West DP; Lacouture ME
Clin Cancer Res; 2010 Sep; 16(17):4452-60. PubMed ID: 20732960
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
Rudin CM; Liu W; Desai A; Karrison T; Jiang X; Janisch L; Das S; Ramirez J; Poonkuzhali B; Schuetz E; Fackenthal DL; Chen P; Armstrong DK; Brahmer JR; Fleming GF; Vokes EE; Carducci MA; Ratain MJ
J Clin Oncol; 2008 Mar; 26(7):1119-27. PubMed ID: 18309947
[TBL] [Abstract][Full Text] [Related]
15. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.
Gridelli C; Maione P; Amoroso D; Baldari M; Bearz A; Bettoli V; Cammilluzzi E; Crinò L; De Marinis F; Di Pietro FA; Grossi F; Innocenzi D; Micali G; Piantedosi FV; Scartozzi M
Crit Rev Oncol Hematol; 2008 May; 66(2):155-62. PubMed ID: 18083041
[TBL] [Abstract][Full Text] [Related]
17. Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash.
Eriksen JG; Kaalund I; Clemmensen O; Overgaard J; Pfeiffer P
Support Care Cancer; 2017 Jul; 25(7):2179-2185. PubMed ID: 28197850
[TBL] [Abstract][Full Text] [Related]
18. Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Steins MB; Reinmuth N; Bischoff H; Kindermann M; Thomas M
Onkologie; 2010; 33(12):704-9. PubMed ID: 21124044
[TBL] [Abstract][Full Text] [Related]
19. Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents.
Rhee J; Oishi K; Garey J; Kim E
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S101-6. PubMed ID: 16336749
[TBL] [Abstract][Full Text] [Related]
20. Skin problems and EGFR-tyrosine kinase inhibitor.
Kozuki T
Jpn J Clin Oncol; 2016 Apr; 46(4):291-8. PubMed ID: 26826719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
